Abstract
Eletriptan (Relpax) is a novel 5-hydroxytryptamine (serotonin)1D/1B agonist currently in development for the acute treatment of migraine. The aim of this work was to evaluate the relative induction potency of eletriptan in vitro compared with well characterized cytochrome P-450 (CYP) inducers with primary cultures of human hepatocytes and to relate this to the situation in vivo. Eletriptan was a weak inducer of CYP3A4 protein and cyclosporin A oxidation in four of the six cultures used, whereas rifampicin was a potent inducer in all cultures. Induction was concentration dependent and not detectable at eletriptan concentrations of 5 μM and lower. The amplitude of the increase in CYP3A4 protein and activity by 25 μM eletriptan was significantly lower, with a mean of 19 (P = .0015) and 26% (P = .0002), respectively, of that observed in response to 25 μM rifampicin. CYP2A6, a protein with minor pharmacological implication, also was induced by eletriptan and rifampicin in two cultures but was not detected in the others. The levels of other CYP proteins, including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP2E1, were not affected by eletriptan. Because the maximum blood concentration of eletriptan in humans after a therapeutic dose (maximum 80 mg) is 0.5 μM, the in vitro model would predict no clinically significant induction of CYP3A4 protein in vivo. This has been confirmed subsequently in a clinical study, with 6β-hydroxycortisol/cortisol ratios as marker of CYP3A4 activity. Eletriptan is therefore not an inducer of CYP3A4 at clinical doses.
Footnotes
-
Send reprint requests to: Dr. Patrick Maurel, Institut National de la Santé et de la Recherche Médicale U128, Centre National de la Recherche Scientifique IFR24, 1919 Route de Mende, 34293 Montpellier (Cedex 05), France. E-mail:maurel{at}u128.crbm.cnrs-mop.fr
- Abbreviations used are::
- CYP
- cytochrome P-450
- RIF
- rifampicin
- TCDD
- 2,3,7,8-tetrachlorodibenzo(p)dioxin
- DMSO
- dimethyl sulfoxide
- ECL
- enhanced chemiluminescence
- GAPDH
- glyceraldehyde 6-phosphate dehydrogenase
- Received July 9, 1999.
- Accepted September 27, 1999.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|